NMR measurements of NMR biomarker GlycA
OwnerJames D. Otvos, Irina Y. Shalaurova +2inventors
InventorsJames D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Life of this patent
Estimating the term…
Abstract
Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
Claims19
A method of measuring GlycA, comprising:
- electronically obtaining a composite NMR spectrum of a fitting region of a biosample of a subject;
- electronically deconvolving the composite NMR spectrum using a defined deconvolution model with high density lipoprotein (HDL) components, low density lipoprotein (LDL) components, VLDL (very low density lipoprotein)/chylomicron components, and a plurality of curve fit functions associated with at least a GlycA peak region;
- and
- electronically generating a measure of GlycA using the curve fit functions.
A system, comprising:
- an NMR spectrometer for acquiring at least one NMR spectrum of an in vitro biosample;
- and
- at least one processor in communication with the NMR spectrometer, the at least one processor configured to obtain an NMR measurement of GlycA using the at least one NMR spectrum.
An NMR analyzer comprising:
- a NMR spectrometer;
- and
- at least one processor in communication with the spectrometer configured to obtain NMR signal of a defined single peak region of NMR spectra associated with GlycA of a fluid specimen and generate a report providing a GlycA level.
Dependencies are inferred from the claim text.